Generate Biomedicines/$GENB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Generate Biomedicines
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
- Ticker
- $GENB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 312
- Headquarters
- Somerville, United States
- Website
- generatebiomedicines.com
GENB Metrics
BasicAdvanced
$1.6B
-
-$3.28
-
-
Price and volume
Market cap
$1.6B
52-week high
$22.67
52-week low
$11.00
Average daily volume
1M
Financial strength
Current ratio
8.303
Quick ratio
8.076
Long term debt to equity
0.107
Total debt to equity
0.137
Interest coverage (TTM)
-328.93%
Profitability
EBITDA (TTM)
-249.548
Gross margin (TTM)
-807.30%
Net profit margin (TTM)
-897.71%
Operating margin (TTM)
-991.15%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$80,000
Management effectiveness
Valuation
Price to revenue (TTM)
38.924
Price to book
3.54
Price to tangible book (TTM)
3.54
Price to free cash flow (TTM)
-4.219
Free cash flow yield (TTM)
-23.70%
Free cash flow per share (TTM)
-2.98
Growth
What the Analysts think about GENB
Analyst ratings (Buy, Hold, Sell) for Generate Biomedicines stock.
Analyst projections of the future price of Generate Biomedicines stock.
Bulls say / Bears say
A single 300 mg dose of GB-0895 produced sustained reductions in key asthma biomarkers for at least six months in Phase 1, supporting the prospect of twice-yearly injections. The data also showed a roughly 98-day half-life and no treatment-related serious adverse events. (Generate:Biomedicines)
Zealand Pharma will pay $30 million upfront and may pay substantial milestones and royalties for two AI-designed metabolic drug programmes. Zealand taking over later clinical development and commercialisation gives Generate a partner-funded route to build value from its platform. (Generate:Biomedicines)
Generate is broadening its clinical pipeline beyond its lead asthma drug: GB-5267 has dosed its first patient in a Phase 1 ovarian-cancer trial, while GB-4362 has begun dosing in a Phase 1 study and has FDA Fast Track designation. Progress across distinct programmes could reduce reliance on a single asset over time. (Generate:Biomedicines, Generate Biomedicines)
The encouraging GB-0895 results so far are early Phase 1 biomarker and safety findings, not proof that the drug prevents asthma attacks or improves patients’ health. That efficacy test is still ahead in the Phase 3 trials. (Generate:Biomedicines, Investing.com)
Generate reported $457.4 million in cash and investments at the end of June, but expects that to fund its current plan only into the first half of 2028 and says it will need more capital for longer-term operations. Ongoing losses and costly trials make future fundraising—and potential dilution—a material risk. (Generate Biomedicines)
The Phase 3 asthma trials are expected to finish enrolment only by the end of 2027, with results expected towards the end of 2028, leaving investors with a long wait for a major value test. Established asthma biologics and other long-acting anti-TSLP programmes also mean that a six-month dosing schedule may not be enough to win market share. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
GENB Financial Performance
Revenues and expenses
GENB Earnings Performance
Company profitability
Upcoming events
No upcoming events
GENB News
AllArticlesVideos
Funds containing GENB
Fund name | Fund size | $GENB weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 1.05% |
ARK Genomic Revolution£ARCG | $123M | 1.05% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.